A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...
SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis (MS), show the findings of the INFORMS study. The findings, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results